Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (LGND)
NASDAQ:LGND
Earnings Data
Report Date
Nov 05, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
1.92Last Year’s EPS
1.84Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant growth in royalty revenue, strategic investments, and successful product launches. However, increased operating expenses and tax rate concerns were noted. The positive aspects significantly outweigh the challenges.Company Guidance
Strong Royalty Revenue Growth
Royalty revenue grew 57% over the same quarter last year, and adjusted EPS increased 14%. Total revenue for Q2 '25 grew 15% year-over-year to $47.6 million.
Strategic Investments and Partnerships
Ligand completed a strategic merger of Pelthos with Channel Therapeutics and partnered with Medtronic and Orchestra BioMed to support development of promising cardiovascular therapies, which have received 4 breakthrough device designations from the FDA.
Successful Launch and Market Expansion
Pelthos launched Zelsuvmi into the market, and the current market value of Ligand's equity stake in Pelthos is approximately $100 million. The company expects Zelsuvmi to achieve $175 million in peak sales.
Merck's Acquisition of Verona
Merck announced a $10 billion acquisition of Verona, which could accelerate the global launch of O2vir, where Ligand receives a 3% royalty on worldwide net sales.
Positive Clinical Trial Developments
Nuance Pharma announced positive data and completion of its Phase III trial in China for an asset partnered with Verona. FDA granted Recordati orphan drug designation for Qarziba in Ewing sarcoma.
LGND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LGND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $142.40 | $146.32 | +2.75% |
May 08, 2025 | $105.62 | $102.51 | -2.94% |
Feb 27, 2025 | $115.01 | $115.67 | +0.57% |
Nov 07, 2024 | $116.90 | $129.90 | +11.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ligand Pharma (LGND) report earnings?
Ligand Pharma (LGND) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).
What is Ligand Pharma (LGND) earnings time?
Ligand Pharma (LGND) earnings time is at Nov 05, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LGND EPS forecast?
LGND EPS forecast for the fiscal quarter 2025 (Q3) is 1.92.